ADAMs as new therapeutic targets for triple-negative breast cancer.
M. Mullooly
No relevant relationships to disclose
P. M. McGowan
No relevant relationships to disclose
S. U. Sukor
No relevant relationships to disclose
S. F. Madden
No relevant relationships to disclose
E. McDermott
No relevant relationships to disclose
J. Crown
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
N. O'Donovan
No relevant relationships to disclose
M. J. Duffy
No relevant relationships to disclose